- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress
September 25th 2024, 2:05pm
Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.
Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC
September 25th 2024, 12:00pm
Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.
Breastfeeding During Endocrine Therapy Interruption Is Feasible, Does Not Adversely Affect Recurrence Rates in HR+ Breast Cancer
September 24th 2024, 1:00pm
Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.
NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC
September 19th 2024, 5:13pm
The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.
CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC
September 19th 2024, 12:00pm
Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.
Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer
September 18th 2024, 9:32pm
Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.
Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer
September 18th 2024, 6:00pm
IASLC World Conference on Lung Cancer
Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.
Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer
September 18th 2024, 2:40pm
Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.
Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers
September 18th 2024, 2:00pm
Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.
Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC
September 17th 2024, 8:00pm
Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.
Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC
September 17th 2024, 6:00pm
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma
September 17th 2024, 12:00pm
Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
September 16th 2024, 11:10pm
Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status
September 16th 2024, 9:20pm
Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.
Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos
September 16th 2024, 8:49pm
Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.
GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers
September 16th 2024, 8:30pm
AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.
AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors
September 16th 2024, 8:15pm
AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.
Nonoperative Management Maintains DFRS, Promotes Organ Preservation in pMMR Rectal Cancer
September 16th 2024, 7:24pm
In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.
Inavolisib Demonstrates Safety, Disease Control in PIK3CA-Mutated Solid Tumors
September 16th 2024, 7:21pm
Inavolisib demonstrated a favorable safety profile and generated disease control in patients with tumors harboring PIK3CA mutations.
Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC
September 16th 2024, 6:15pm
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.